Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implications

Area of Science:

• Oncology
• Genitourinary Cancer Research
• Biomarker Discovery

Background:

• Genitourinary cancers (bladder, prostate, renal, testicular) constitute 25% of global solid tumors.
• Significant progress in cancer diagnostics and therapeutics has been made.
• Liquid biopsy (LB) has emerged as a novel technology in oncology.

Purpose of the Study:

• To review the latest advancements in liquid biopsy applications for genitourinary cancers.
• To highlight LB's role in diagnostic and prognostic characterization.
• To discuss the potential and challenges of LB in genitourinary oncology.

Main Methods:

• Analysis of circulating tumor DNA (ctDNA).
• Detection of circulating tumor cells (CTCs).
• Isolation and analysis of extracellular vesicles (EVs) and non-coding RNAs.

Main Results:

• LB provides less invasive alternatives to traditional biopsies.
• LB applications include early screening, diagnosis, prognosis, and treatment monitoring.
• LB can detect minimal residual disease and recurrence before radiological evidence.

Conclusions:

• Liquid biopsy shows significant promise for genitourinary cancer management.
• Standardization and validation in large trials are crucial for clinical adoption.
• Further research is needed to overcome current challenges and optimize LB protocols.